STOCK TITAN

Tandem Diabetes Care (TNDM) COO logs RSU vesting, 31,741 shares held after tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported equity compensation activity. On July 15, 2026, 3,636 restricted stock units converted into common stock, bringing his direct holdings to 31,741 shares. To satisfy tax withholding on the vesting, the company withheld 1,926 shares at $15.28 per share; no shares were sold in the market. After this vesting, 14,545 RSUs from a July 2024 grant under the 2023 Long-Term Incentive Plan remain outstanding.

Positive

  • None.

Negative

  • None.
Insider Kyrillos Jean-Claude
Role EVP & Chief Operating Officer
Type Security Shares Price Value
Exercise Restricted Stock Unit 3,636 $0.00 --
Exercise Common Stock 3,636 $0.00 --
Tax Withholding Common Stock 1,926 $15.28 $29K
Holdings After Transaction: Restricted Stock Unit — 14,545 shares (Direct); Common Stock — 31,741 shares (Direct)
Footnotes (1)
  1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. One-third of the RSUs granted on July 14, 2024 vested on July 14, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Shares withheld for taxes 1926.0000 shares Common stock withheld to satisfy tax withholding requirements on RSU vesting
Tax withholding price $15.2800 per share Value used for shares withheld to cover tax obligations
Shares from RSU conversion 3636.0000 shares Common shares acquired upon exercise/conversion of restricted stock units
Common shares after transactions 31741.0000 shares Direct holdings of common stock following the reported Form 4 transactions
RSUs remaining after vesting 14545.0000 units Restricted stock units outstanding after the 3,636-unit conversion
RSU grant year 2024 Year of the RSU award under the Tandem Diabetes Care 2023 Long-Term Incentive Plan
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit" with underlying common stock"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding requirements financial
"Shares withheld by the Issuer to satisfy tax withholding requirements"
Long-Term Incentive Plan financial
"pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
contingent right financial
"Each RSU represents a contingent right to receive either one share of common stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did TNDM executive Jean-Claude Kyrillos report?

Jean-Claude Kyrillos reported 3,636 RSUs converting into common stock and 1,926 shares withheld by Tandem Diabetes Care for taxes at $15.28 per share. His direct holdings rose to 31,741 common shares, with 14,545 RSUs still outstanding.

Did the TNDM COO sell any shares in this Form 4 filing?

No. The filing states that no shares were sold. Instead, 1,926 shares of Tandem Diabetes Care common stock were withheld by the issuer solely to satisfy tax withholding requirements related to vesting restricted stock units.

How many Tandem Diabetes Care (TNDM) shares does the COO own after this Form 4?

After the reported transactions, Jean-Claude Kyrillos directly owns 31,741 shares of Tandem Diabetes Care common stock. He also continues to hold 14,545 restricted stock units (RSUs) that can settle in shares or cash at the company’s discretion.

What happened to the restricted stock units in the TNDM COO’s grant?

On July 15, 2026, 3,636 RSUs converted into an equal number of common shares, reducing the RSU balance to 14,545 units. The RSUs come from a July 2024 grant under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan.

Was the TNDM COO’s Form 4 transaction under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox was not marked, and the footnotes do not reference any trading plan. The activity relates to RSU vesting and tax withholding, rather than an open-market trading program.

What are the key terms of the TNDM COO’s RSU award mentioned in the Form 4?

The RSUs were awarded in July 2024 under Tandem Diabetes Care’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash in lieu, at the company’s discretion, subject to the plan’s vesting schedule.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kyrillos Jean-Claude

(Last)(First)(Middle)
12400 HIGH BLUFF DRIVE

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP & Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/15/2026M3,636A$031,741D
Common Stock07/15/2026F(1)1,926D$15.2829,815D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)(3)07/15/2026M3,636 (4) (4)Common Stock3,636$014,545D
Explanation of Responses:
1. Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
2. Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
3. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
4. One-third of the RSUs granted on July 14, 2024 vested on July 14, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Remarks:
/s/ Jerilyn Laskie, Attorney-in-Fact for Jean-Claude Kyrillos07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)